Oppenheimer Releases Biogen Idec Company Update - Biogen (NASDAQ:BIIB)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

According to a research report published by Oppenheimer, Biogen Idec Inc. (NASDAQ: BIIB) has complied with a FDA mandated label update.“With the addition of JCV as a risk factor, we believe Tysabri's label addresses the most concerning PML risk factor. Together with the commercial availability of the test, we expect substantially greater JCV testing in the US MS patient population, and higher numbers of known JCV-negative pts,” Oppenheimer commented.Oppenheimer maintains its Outperform rating and $127.00 PT on Biogen Idec Inc., which closed Friday at $118.14.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!